TW201835331A - 製備醣蛋白-藥物共軛物之方法 - Google Patents
製備醣蛋白-藥物共軛物之方法 Download PDFInfo
- Publication number
- TW201835331A TW201835331A TW106146600A TW106146600A TW201835331A TW 201835331 A TW201835331 A TW 201835331A TW 106146600 A TW106146600 A TW 106146600A TW 106146600 A TW106146600 A TW 106146600A TW 201835331 A TW201835331 A TW 201835331A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- glycoprotein
- conjugate
- formula
- antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 239000003814 drug Substances 0.000 title claims description 14
- 229940079593 drug Drugs 0.000 title description 6
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 48
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 38
- 125000005647 linker group Chemical group 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 150000004676 glycans Chemical class 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 235000000346 sugar Nutrition 0.000 claims description 25
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 19
- -1 F (ab ') 2 Proteins 0.000 claims description 17
- 125000000468 ketone group Chemical group 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229940100198 alkylating agent Drugs 0.000 claims description 12
- 239000002168 alkylating agent Substances 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 108010056771 Glucosidases Proteins 0.000 claims description 11
- 102000004366 Glucosidases Human genes 0.000 claims description 11
- 229930194542 Keto Chemical group 0.000 claims description 10
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 210000003292 kidney cell Anatomy 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 230000001588 bifunctional effect Effects 0.000 claims description 5
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 5
- 229930195731 calicheamicin Natural products 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000003973 alkyl amines Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 239000003080 antimitotic agent Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 235000019833 protease Nutrition 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 238000006268 reductive amination reaction Methods 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 3
- 150000004982 aromatic amines Chemical class 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 241000700157 Rattus norvegicus Species 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000717 sertoli cell Anatomy 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 238000012650 click reaction Methods 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000005264 aryl amine group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001925 cycloalkenes Chemical class 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 53
- 239000000047 product Substances 0.000 description 44
- 108091022873 acetoacetate decarboxylase Proteins 0.000 description 43
- 238000004587 chromatography analysis Methods 0.000 description 43
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 37
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 31
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 30
- 239000000562 conjugate Substances 0.000 description 29
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 16
- 229960000575 trastuzumab Drugs 0.000 description 15
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 101150029707 ERBB2 gene Proteins 0.000 description 11
- 239000000611 antibody drug conjugate Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 101100330725 Arabidopsis thaliana DAR4 gene Proteins 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 8
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 8
- 150000001299 aldehydes Chemical group 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000011565 manganese chloride Substances 0.000 description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 229960001612 trastuzumab emtansine Drugs 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 6
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 6
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001540 azides Chemical group 0.000 description 4
- 229960000455 brentuximab vedotin Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 108010059074 monomethylauristatin F Proteins 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101710186714 2-acylglycerol O-acyltransferase 1 Proteins 0.000 description 3
- 102100024296 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 150000002482 oligosaccharides Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 2
- RNQVGVKGGAODSC-MEXJFSEESA-N 1-[(3R,4R,5R,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]ethanone Chemical compound C(C)(=O)[C@]1([C@H](C(O)O[C@@H]([C@H]1O)CO)N)O RNQVGVKGGAODSC-MEXJFSEESA-N 0.000 description 2
- 101710186725 2-acylglycerol O-acyltransferase 2 Proteins 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- CMSYVPIXXGNYEG-RTRLPJTCSA-N N'-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical group CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CMSYVPIXXGNYEG-RTRLPJTCSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000013587 protein N-linked glycosylation Effects 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 1
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010002020 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 108010053481 Antifreeze Proteins Proteins 0.000 description 1
- 101100330723 Arabidopsis thaliana DAR2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- DPUMHUVMIQPBPA-LDHWTSMMSA-N BrC([C@H]([C@H]([C@@H]([C@@H](C(O)(Br)Br)O)O)O)O)(O)Br Chemical compound BrC([C@H]([C@H]([C@@H]([C@@H](C(O)(Br)Br)O)O)O)O)(O)Br DPUMHUVMIQPBPA-LDHWTSMMSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MKAQIVJJIWVCPG-FNRFDOJGSA-N C(C)N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O)CO)C(N)=N Chemical compound C(C)N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O)CO)C(N)=N MKAQIVJJIWVCPG-FNRFDOJGSA-N 0.000 description 1
- 229940124293 CD30 monoclonal antibody Drugs 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 244000290594 Ficus sycomorus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 101000663048 Homo sapiens Transmembrane and coiled-coil domain protein 3 Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001661345 Moesziomyces antarcticus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- XRFMPFAGPMPRII-ZQLGFOCFSA-N N(=[N+]=[N-])CC(=O)NN[C@H]1C(O)O[C@@H]([C@H]([C@@H]1O)O)CO Chemical compound N(=[N+]=[N-])CC(=O)NN[C@H]1C(O)O[C@@H]([C@H]([C@@H]1O)O)CO XRFMPFAGPMPRII-ZQLGFOCFSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MKFCKLDKSA-N N-acetyl-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MKFCKLDKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- JPTXEFFSEFKJOF-UHFFFAOYSA-N NCC(=O)O.NCC(=O)O.NCC(=O)O.SCC(=N)N Chemical compound NCC(=O)O.NCC(=O)O.NCC(=O)O.SCC(=N)N JPTXEFFSEFKJOF-UHFFFAOYSA-N 0.000 description 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
- IQZQOJLADZRROZ-UHFFFAOYSA-N OC1N(CCNCCNCCNC1)CCC Chemical compound OC1N(CCNCCNCCNC1)CCC IQZQOJLADZRROZ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100037737 Transmembrane and coiled-coil domain protein 3 Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 101710090322 Truncated surface protein Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 229950009221 chidamide Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-ARJAWSKDSA-N cis-but-2-ene Chemical compound C\C=C/C IAQRGUVFOMOMEM-ARJAWSKDSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- VMNKSZFNJIQWOL-UHFFFAOYSA-N ethanamine ethene Chemical compound C=C.C=C.C=C.C(C)N VMNKSZFNJIQWOL-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 150000002704 mannoses Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本發明提供一種用於修飾醣蛋白之方法。本發明亦提供一種用於製造醣蛋白-酬載共軛物之方法,以及由此產生之共軛物。
Description
本發明係關於一種修飾醣蛋白以使得醣蛋白包含一或多個三甘露糖基核心的方法。本發明亦關於醣蛋白-酬載(payload)共軛物,其包含本發明之醣蛋白及相關酬載。
治療性蛋白藥物已在臨床上廣泛使用,且因為其價值高、特異性高及毒性低的優勢,所以世界上一些大型醫藥公司致力於研發此類藥物進行臨床試驗。此等治療性蛋白中之大部分係單株抗體。儘管有一些患者對其臨床結果感到滿意,但是臨床試驗數據表明,此等抗體中之一些的治療效果仍需改良,尤其是在癌症治療中。為了克服此缺點,科學家開始聚焦於透過一些技術來修飾此等臨床抗體,以便增進其在癌症療法中之功效。在此等技術中,抗體-藥物共軛物(antibody-drug conjugate,ADC)因為其對於化學製造管制(chemistry, manufacturing and control,CMC)友善、對使用者友善且副作用較低而備受關注。迄今為止,市場上有4種治療性抗體-藥物共軛物可供使用,包括Mylotarg®
、Adcetris®
、Besponsa®
及Kadcyla®
;還有許多其他藥物正在研發當中(Kubizek F1, Eggenreich B1, Spadiut O1. Protein Pept Lett. 2017,24(8):686-695;Fischer E., Roger Schibli R. Antibodies 2015, 4, 197-224;Sapra, P., Hooper, A., O'Donnell, C.及Gerber, H.-P. Expert Opin. Investig. Drugs 2011, 20, 1131-1180;Flygare, J., Pillow, T.及Aristoff, P., Chem. Biol. Drug Des. 2013, 81, 113-121;Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.及Junutula, J.R. Site-specific antibody drug conjugates for cancer therapy. MAbs 2013, 6, 34-45)。 在此等臨床ADC中,Kadcyla及Mylotarg係藉由酬載或連接基團與離胺酸殘基之胺基隨機共軛所形成,而Adcetris®
(維本妥昔單抗(brentuximab vedotin) (cAC10-vcMMAE,SGN-35))則係嵌合抗CD30單株抗體,其中融合了鼠抗CD30抗體AC10之可變重鏈區與輕鏈區。平均4 (2-8)個MMAE分子與SGN-30架構共軛。MMAE之共軛點係藉由鏈間雙硫鍵之溫和還原產生的半胱胺酸殘基之隨機-SH基團。連接基團由硫醇反應性順丁烯二醯亞胺基己醯基間隔子、二肽纈胺酸-瓜胺酸連接基團及PABC間隔子組成(Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX等人 cAC10-vcMMAE. Blood 2003, 4 ,1458-65)。雖然該等技術容易使酬載或連接基團與抗體共軛,但是因為多個離胺酸序列及抗體中之半胱胺酸殘基之最佳還原反應的問題,這兩種技術難以控制共軛物之藥物與抗體之比(drug-to-antibody ratio,DAR)。此等現象經常造成抗體產物之異質性且誘發CMC問題。一些文獻甚至指出此類型之第一代非位點特異性ADC具有PK及免疫原性之缺點。 為解決第一代ADC之此等缺點,研發了位點特異性ADC平台,包括SMART標籤、非天然胺基酸任何酪胺酸、治療性轉肽酶(sortase)、硫橋(Thio-Bridge)等。正如吾人所期望的,此等技術能夠藉由對親本抗體中之一些特異性位點或結構域進行工程改造而產生均質ADC產物。舉例而言,硫橋技術將連接基團及酬載與抗體之部分還原之雙硫鍵連接。SMART標籤係藉由使抗體之相鄰序列突變為細菌氧化酶之受質序列的技術。所得產物與甲醛一起用作為連接基團與酬載之連接位點。正如預期,此等第二代ADC技術能夠產生具有獨特的DAR及高均質性的ADC產物。然而,因為天然抗體之突變,ADC產物可能具有PK及免疫原性問題。目前,經由N-糖基化使酬載與抗體共軛吸引了大量關注,此係因為成功研發出了抗體之糖基化工程改造(glycolengineering)。 所有天然存在之IgG及重組抗體均在重鏈CH2恆定區中之每一者的位置297處具有胺基酸天冬醯胺酸(Asn297),其係一個N-糖基化位點。藉由在哺乳動物細胞中之糖基化及後修飾,經由IgG上之N-糖基化形成兩個雙觸狀聚醣部分,且雙觸狀聚醣部分各自基本上由具有下式之至少7個糖部分構成:, 其中第一GlcNAc (GlcNAc1
)分別鍵結至抗體之Asn297及第二GlcNAc (GlcNAc2
),且視情況鍵結至海藻糖(Fuc);GlcNAc2
進一步鍵結至第一甘露糖(Man1
);第二及第三甘露糖(Man2
及Man3
)分別鍵結至Man1
之α-1,3及α-1,6位置;且另外兩個GlcNAc糖(GlcNAc3
及GlcNAc4
)分別鍵結至Man2
及Man3
之β-1,2位置。具有該等聚醣部分與海藻糖之抗體表示為G0F,然而,當海藻糖部分不存在時,抗體係G0。(T. Shantha RajuMAbs. 2012年5月1日; 4(3): 385-391)。當GlcNAc3
或GlcNAc4
鍵結至額外的半乳糖時,抗體表示為G1F/G1抗體。當抗體之聚醣部分中之末端GlcNAc糖分別鍵結至兩個額外的半乳糖時,抗體表示為G2F/G2抗體。由哺乳動物細胞產生之抗體一般可包括G0F (大於約40%)、G1F (約30%-40%)及G2F (小於1%)以及極少量之連接至唾液酸的G1F/G1及G2F/G2。 因為在N297聚醣中之各分枝位點進行工程改造可維持結構完整且產生一些功能多樣性(例如抗體之ADCC、半衰期及CDC),已研發出一些N297糖基化工程改造ADC平台且其中一些產品正處於臨床試驗階段。WO 2014/164534 A2、WO 2014/065661 A1、WO 2015/032899 A1、WO 2015/057064 A1、WO 2015/157446 A1、US 8716033 B2、US 7416858 B2、EP 2753752 B3及綜述文章(Bioconjug Chem.; 2015年11月18日; 26(11):2070-5)已揭示諸多用於抗體藥物共軛之經修飾聚醣部分。然而,在此等技術中無法充分控制抗體-藥物共軛中之藥物抗體比(DAR)且不能實現酬載多樣性,因此在此項技術中需要控制ADC之藥物抗體比且提高酬載多樣性。本發明滿足此需要且提供其他益處。
本發明之一個態樣提供一種用於製造包含式(1)之結構的醣蛋白-酬載共軛物的方法:。 本發明之另一態樣提供一種用於製造包含式(5)之結構的醣蛋白-酬載共軛物的方法:。 本發明之另一態樣提供一種用於製造包含式(7)之結構的醣蛋白-酬載A/B共軛物的方法:。 本發明之另一態樣提供可藉由本發明方法獲得之醣蛋白-酬載共軛物。
除非另外定義,否則本文中所用之所有技術及科學術語具有與本發明所屬領域之一般技術者通常所理解相同之含義。雖然可在實施或測試本發明時使用類似於或等效於本文所述之方法及材料的任何方法及材料,但現在描述較佳的方法及材料。本文特別提及的所有公開案及專利出於所有目的以引用的方式併入本文中,包括描述及揭示公開案中所報導、可聯合本發明使用的化學品、細胞株、載體、動物、儀器、統計分析及方法。本說明書中所引用的所有參考文獻視為此項技術之技能水準之指示。 縮寫
應注意,如本文及隨附申請專利範圍中所用,除非上下文另外清楚地規定,否則單數形式「一(a/an)」及「該」包括複數個指示物。同樣,在本文中,術語「一(a或an)」、「一或多個」及「至少一個」可互換使用。亦應注意,術語「包含」、「包括」及「具有」可互換使用。 通常,本文中範圍表述為自「約」一個特定值及/或至「約」另一特定值。當表述此類範圍時,實施例包括自一個特定值及/或至另一特定值之範圍。類似地,當值藉由使用詞語「約」表述為近似值時,應理解特定值形成另一實施例。將進一步理解,範圍中之每一者之端點無論與另一端點相關還是與另一端點無關均為有意義的。如本文所用,術語「約」係指± 20%、± 15%、± 10%、± 9%、± 8%、± 7%、± 6%、± 5%、± 4%、± 3%、± 2%、± 1%、± 0.5%或± 0.25%。 當提及調配物組分時,例如「藥劑」之所用術語意欲不僅涵蓋特定分子實體,且亦涵蓋其醫藥學上可接受之類似物,包括(但不限於)鹽、酯、醯胺、前藥、共軛物、活性代謝物及其他此類衍生物、類似物及相關化合物。 本文所用之通用術語「糖」指示單醣,例如葡萄糖(Glc)、半乳糖(Gal)、甘露糖(Man)及海藻糖(Fuc),以及單醣衍生物,諸如胺基糖及糖酸,例如葡萄糖胺(GlcN)、半乳糖胺(Galn)、N-乙醯葡萄糖胺(GlcNAc)、N-疊氮基乙醯葡萄糖胺(GlcNAZ)、N-乙醯半乳糖胺(GlaNAc)、N-乙醯神經胺糖酸(NeuNAc)、N-乙醯胞壁酸(MurNAc)、葡萄糖醛酸(GlcA)及艾杜糖醛酸(iduronic acid,IdoA)。 如本文所用,術語「蛋白質」可包括具有天然胺基酸序列之多肽,以及變異體及經修飾形式,不管其來源或製備模式為何。具有天然胺基酸序列之蛋白質係具有如從自然界獲得之相同胺基酸序列的蛋白質。該等天然序列蛋白質可從自然界分離或可使用標準重組及/或合成方法製備。天然序列蛋白質明確涵蓋天然存在之截短或可溶形式、天然存在之變異體形式(例如交替剪接形式)、天然存在之對偶基因變異體及包括轉譯後修飾之形式。天然序列蛋白質包括在一些胺基酸殘基之轉譯後修飾之後的蛋白質,轉譯後修飾諸如糖基化或磷酸化或其他修飾。 如本文所用,術語「醣蛋白」係指包含一或多個共價鍵結至蛋白質的單醣或寡醣鏈的蛋白質。聚醣可附接至蛋白質之羥基(O連接型糖基),例如附接至絲胺酸、蘇胺酸、酪胺酸、羥基離胺酸或羥基脯胺酸之羥基,或附接至例如天冬醯胺酸或精胺酸之蛋白質上之醯胺(N-醣蛋白),或附接至例如色胺酸之蛋白質上之碳(C-醣蛋白)。醣蛋白可包含超過一個聚醣,可包含一或多個單醣與一或多個寡醣聚醣之組合,且可包含N連接型、O連接型及C連接型聚醣之組合。醣蛋白之實例包括對細胞表面抗原具有特異性的配體、前列腺特異性膜抗原、南極念珠菌脂肪酶(candida antarctica lipase)、gp41、gp120、紅血球生成素(erythropoietin,EPO)、抗凍蛋白及抗體。 抗體係由免疫系統所產生,能夠識別且結合至特異性抗原的蛋白質。本文中之術語抗體在其最廣泛意義上使用且尤其包括單株抗體、多株抗體、二聚體、多聚體、多特異性抗體(例如雙特異性抗體)、抗體片段及雙鏈與單鏈抗體。術語「抗體」在本文中亦意欲包括人類抗體、人類化抗體、嵌合抗體及特異性結合癌症抗原之抗體。術語「抗體」意欲包括全抗體,還有抗體片段,例如來自裂解抗體的抗體Fab片段、F(ab')2、Fv片段或Fc片段、scFv-Fc片段、微型抗體、雙功能抗體或scFv。此外,該術語包括抗體之經基因工程改造的衍生物。抗體、抗體片段及經基因工程改造之抗體可藉由此項技術中已知之方法獲得。適合的市售抗體包括(但不限於)阿昔單抗(abciximab)、利妥昔單抗(rituximab)、巴利昔單抗(basiliximab)、帕利珠單抗(palivizumab)、英利昔單抗(infliximab)、曲妥珠單抗、阿侖單抗(alemtuzumab)、阿達木單抗(adalimumab)、托西莫單抗(tositumomab)-1131、西妥昔單抗(cetuximab)、替伊莫單抗(ibrituximab tiuxetan)、奧馬珠單抗(omalizumab)、貝伐單抗(bevacizumab)、那他珠單抗(natalizumab)、蘭尼單抗(ranibizumab)、帕尼單抗(panitumumab)、依庫珠單抗(eculizumab)、聚乙二醇化賽妥珠單抗(certolizumab pegol)、戈利木單抗(golimumab)、卡那單抗(canakinumab)、卡妥索單抗(catumaxomab)、優特克單抗(ustekinumab)、托珠單抗(tocilizumab)、奧伐木單抗(ofatumumab)、地諾單抗(denosumab)、貝利單抗(belimumab)、伊匹單抗(ipilimumab)及本妥昔單抗。 可使用多種表現系統(包括原核表現系統及真核表現系統)來產生抗體。在一些實施例中,表現系統係哺乳動物細胞表現系統,諸如融合瘤;或CHO細胞表現系統。諸多此類系統可廣泛地購自商業供應商。在抗體包含VH
及VL
區的實施例中,VH
及VL
區可使用單一載體表現,例如以雙順反子表現單元表現;或在不同啟動子的控制下表現。在其他實施例中,VH
及VL
區可使用個別的載體表現。如本文所述之VH
及VL
區可視情況在N端包含甲硫胺酸。 編碼相關抗體之重鏈及輕鏈的基因可選殖自細胞,例如,編碼單株抗體之基因可選殖自融合瘤且用於產生重組單株抗體。編碼單株抗體之重鏈及輕鏈的基因庫亦可由融合瘤或漿細胞製得。重鏈及輕鏈基因產物之隨機組合產生具有不同抗原特異性之大抗體池。 用於製造單鏈抗體或重組抗體之技術(美國專利第4,946,778號、美國專利第4,816,567號)可適用於製造本發明多肽之抗體。此外,可使用基因轉殖小鼠或諸如其他哺乳動物之其他生物體來表現人類化抗體或人類抗體(參見例如美國專利第5,545,807號;第5,545,806號;第5,569,825號;第5,625,126號;第5,633,425號;第5,661,016號;Marks等人, Bio/Technology 10:779-783 (1992);Lonberg等人, Nature 368:856-859 (1994);Morrison, Nature 368:812-13 (1994);Fishwild等人, Nature Biotechnology 14:845-51 (1996);Neuberger, Nature Biotechnology 14:826 (1996);以及Lonberg及Huszar, Intern. Rev. Immunol. 13:65-93 (1995))。 如本文所用,「GlcNAc1
」、「GlcNAc2
」、「GlcNAc3
」及「GlcNAc4
」分別表示在觸狀聚醣部分之不同位置處的GlcNAc糖。 如本文所用,「」表示包含三個甘露糖之三甘露糖基結構,其中第一甘露糖(Man1
)連接至GlcNAc糖;而第二及第三甘露糖(Man2
及Man3
)分別經由α-1,3及α-1,6醣苷鍵連接至Man1
。 如本文所用,「-(Fuc)0-1
」表示海藻糖係視情況存在,且當存在時,僅有一個海藻糖。 如本文所用,「-(CH2
)0-8
-」表示-CH2
-可存在或可不存在,且當存在時,其可獨立地為1、2、3、4、5、6、7或8個-CH2
-基團。 本發明之一個態樣提供一種用於製造包含式(1)之結構的醣蛋白-酬載共軛物的方法:, 該方法包含以下步驟: (i) 使包含具有式(2)之聚醣的醣蛋白與β-N-乙醯葡萄糖胺酶反應,產生包含式(3)之三甘露糖基核心的經修飾醣蛋白; (ii) 使包含式(3)之三甘露糖基核心之經修飾醣蛋白與UDP-GlcNAc-(CH2
)0-8
-R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶及甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得兩個GlcNAc-(CH2
)0-8
-R糖分別鍵結至Man2
及Man3
各者之β-1,2位置,且藉此形成式(4)之聚醣部分;以及 (iii) 使兩個共軛劑-連接基團-酬載與式(4)之聚醣部分反應,其中兩個共軛劑-連接基團-酬載之酬載相同或不同,產生包含式(1)之結構的醣蛋白-酬載共軛物。 在一些實施例中,兩個酬載不同,酬載可以隨機方式附接至醣蛋白中之四個Man-GlcNAc結構中之任一者。 本發明之另一態樣提供一種用於製造包含式(5)之結構的醣蛋白-酬載共軛物的方法:, 該方法包含以下步驟: (i) 使包含如上文所定義之式(3)之三甘露糖基核心的經修飾醣蛋白與UDP-GlcNAc-(CH2
)0-8
-R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2
)0-8
-R糖鍵結至Man2
之β-1,2位置,且藉此形成包含式(6)之聚醣部分的醣蛋白;以及 (ii) 使共軛劑-連接基團-酬載與包含式(6)之聚醣部分的醣蛋白反應,產生包含式(5)之結構的醣蛋白-酬載共軛物。 在一些實施例中,為了精確控制酬載所附接的位置,可藉由以下步驟產生包含式(7)之結構的醣蛋白-酬載A/B共軛物:(i) 使包含如上文所定義之式(3)之三甘露糖基核心的經修飾醣蛋白與UDP-GlcNAc-(CH2)0-8
-R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2)0-8
-R糖鍵結至Man2
之β-1,2位置,且藉此形成包含如上文所定義之式(6)之聚醣部分的醣蛋白; (ii) 使共軛劑-連接基團-酬載A與包含式(6)之聚醣部分的醣蛋白反應,產生包含式(8)之結構的醣蛋白-酬載A共軛物; (iii) 使包含式(8)之結構的醣蛋白-酬載A共軛物與UDP-GlcNAc-(CH2
)0-8
-R在甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2
)0-8
-R糖鍵結至Man3
之β-1,2位置,且藉此形成包含具有式(9)之聚醣-酬載A部分的醣蛋白;以及 (iv) 使共軛劑-連接基團-酬載B與包含具有式(9)之聚醣-酬載A部分的醣蛋白反應,產生包含式(7)之結構的醣蛋白-酬載A/B共軛物, 其中該酬載A與該酬載B相同或不同。 如本文所用之醣蛋白可例如藉由固態肽合成(例如梅里菲爾德固相合成(Merrifield solid phase synthesis))或重組製造獲得。關於重組製造,將一或多個編碼醣蛋白之聚核苷酸分離且插入載體中以在宿主細胞中進行進一步選殖及/或表現。此類聚核苷酸可使用習知程序容易地分離及定序。可使用熟習此項技術者熟知的方法來構築含有醣蛋白之編碼序列的表現載體。此等方法包括活體外重組DNA技術、合成技術及活體內重組/基因重組。參見例如Maniatis等人, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, N.Y. (1989);及Ausubel等人, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y. (1989)中所述之技術。 如本文所用,β-N-乙醯葡萄糖胺酶表示催化來自寡醣之β-N-乙醯葡萄糖胺殘基之水解的醣苷酶家族。已發現許多β-N-乙醯基-葡萄糖胺酶都具有催化多種類型之β-醣苷鍵的水解能力。在一較佳實施例中,β-N-乙醯葡萄糖胺酶可以係能夠水解位於醣蛋白之末端乙醯葡萄糖胺殘基與N-聚醣之間的β1-2鍵的外切醣苷酶。外切-β-N-乙醯葡萄糖胺酶變異體可自不同來源獲得,諸如鏈球菌屬(Streptococcus spp
.)及關刀豆(Canavalia ensiformis
)。 根據本發明,甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶(MGAT1;GnT-I;EC:2.4.1.101)將N-乙醯基-D-葡萄糖胺自UDP-GlcNAc轉移至末端甘露糖,末端甘露糖經由α1-3醣苷鍵連接至另一糖部分或聚醣。藉由MGAT1轉移之GlcNAc與α3甘露糖之鍵係β1-2醣苷鍵。已發現MGAT1普遍在真核生物中表現,因為其在高基體(Golgi)中是雜合及複雜的N-聚醣生物合成所必需的酶。 根據本發明,甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶(MGAT2;GnT-II;EC 2.4.1.143)將N-乙醯基-D-葡萄糖胺自UDP-GlcNAc轉移至末端甘露糖,末端甘露糖經由α1-6醣苷鍵連接至另一糖部分或聚醣。藉由MGATII轉移之GlcNAc與α6甘露糖之鍵係β1-2醣苷鍵。已發現MGAT2普遍在真核生物中表現,因為其在高基體中是複雜的N-聚醣生物合成所必需的酶。 在一些實施例中,包含具有式(2)之聚醣的醣蛋白與β-N-乙醯葡萄糖胺酶之間的反應係在哺乳動物細胞培養物中進行。在哺乳動物細胞培養物中,在適於表現醣蛋白及β-N-乙醯葡萄糖胺酶之條件下將哺乳動物細胞株培育在培養基中,該哺乳動物細胞株包含:編碼包含具有式(2)之聚醣的醣蛋白的第一聚核苷酸及編碼β-N-乙醯葡萄糖胺酶之第二聚核苷酸。哺乳動物宿主細胞株之實例包括經SV40轉形之猴腎CV1株(COS-7)、人類胚腎株(293或293T細胞)、幼倉鼠腎細胞(baby hamster kidney cell,BHK)、小鼠塞特利氏細胞(mouse sertoli cell) (TM4細胞)、猴腎細胞(CV1)、非洲綠猴腎細胞(VERO-76)、人類子宮頸癌細胞(HELA)、犬腎細胞(MDCK)、水牛鼠肝細胞(BRL 3A)、人類肺細胞(W138)、人類肝細胞(Hep G2)、小鼠乳房腫瘤細胞(MMT 060562)、TRI細胞、MRC 5細胞、FS4細胞、中國倉鼠卵巢(Chinese hamster ovary,CHO)細胞及骨髓瘤細胞株,諸如YO、NS0、P3X63及Sp2/0。 在本發明之一些實施例中,醣蛋白係抗體或其片段。抗體或其片段可為來自裂解抗體之抗體Fab片段、F(ab')2、Fv片段或Fc片段、scFv-Fc片段、微型抗體、雙功能抗體或scFv。在一個較佳實施例中,抗體係賀癌平、曲妥珠單抗或抗TMCC3抗體。 在本發明之一個實施例中,當R係疊氮基(正常名稱是這樣嗎?)且共軛劑係炔基時,共軛劑-連接基團-酬載與-GlcNAc-(CH2
)0-8
-R基團經由點擊反應而反應形成-GlcNAc-(CH2
)0-8
-連接基團-酬載(Angewandte Chemie International Edition. 40 (11): 2004-2021;及Australian Journal of Chemistry. 60 (6): 384-395)。在另一實施例中,當R係酮基或醛且共軛劑係胺基時,共軛劑-連接基團-酬載與-GlcNAc-(CH2
)0-8
-R基團經由還原胺化而反應形成-GlcNAc-(CH2
)0-8
-連接基團-酬載(J. Org. Chem., 2010, 75, 5470-5477;及Synthesis, 2011, 490-496)。在另一實施例中,當R係酮基或醛且共軛劑係β-芳基乙胺基時,共軛劑-連接基團-酬載與-GlcNAc-(CH2
)0-8
-R基團經由皮克特-施彭格勒反應(Pictet-Spengler reaction)而反應形成-GlcNAc-(CH2
)0-8
-連接基團-酬載(Bioconjugate Chem., 2013, 24 (6), 第846-851頁)。 在一些實施例中,當使用醣蛋白-酬載共軛物來治療個體之疾病時,酬載可為治療劑。治療劑可為細胞抑制劑或細胞毒性劑或帶有相應放射性同位素之同位素螯合劑。細胞抑制劑或細胞毒性劑之實例包括(但不限於)抗代謝物(例如氟尿嘧啶(5-FU)、氟尿苷(5-FUdR)、甲胺喋呤(methotrexate)、甲醯四氫葉酸、羥基尿素、硫鳥嘌呤(6-TG)、巰嘌呤(6-MP)、阿糖胞苷、噴司他汀(pentostatin)、氟達拉濱磷酸鹽(fludarabine phosphate)、克拉屈濱(cladribine) (2-CDA)、天冬醯胺酸酶、吉西他濱(gemcitabine)、卡培他濱(capecitibine)、硫唑嘌呤(azathioprine)、胞嘧啶甲胺喋呤、甲氧苄啶(trimethoprim)、乙胺嘧啶(pyrimethamine)或培美曲塞(pemetrexed));烷基化劑(例如美法侖(cmelphalan)、苯丁酸氮芥(chlorambucil)、白消安(busulfan)、噻替派(thiotepa)、異環磷醯胺(ifosfamide)、卡莫司汀(carmustine)、洛莫司汀(lomustine)、司莫司汀(semustine)、鏈脲佐菌素(streptozocin)、達卡巴嗪(dacarbazine)、絲裂黴素C (mitomycin C)、環磷醯胺(cyclophosphamide)、甲基二(氯乙基)胺(mechlorethamine)、烏拉莫司汀(uramustine)、二溴甘露醇(dibromomannitol)、四硝酸酯(tetranitrate)、丙卡巴肼(procarbazine)、六甲蜜胺(altretamine)、米托唑胺(mitozolomide)或替莫唑胺(temozolomide));類烷基化劑(例如順鉑(cisplatin)、卡鉑(carboplatin)、奈達鉑(nedaplatin)、奧沙利鉑(oxaliplatin)、沙鉑(satraplatin)或三鉑(triplatin));DNA小溝烷基化劑(例如倍癌黴素(duocarmycin),諸如CC-1065,及其任何類似物或衍生物;吡咯并苯并二氮呯(pyrrolobenzodiazapene)或其任何類似物或衍生物);蒽環黴素(anthracycline) (例如道諾黴素(daunorubicin)、小紅莓(doxorubicin)、表柔比星(epirubicin)、艾達黴素(idarubicin)或戊柔比星(valrubicin));抗生素(例如放線菌素D (dactinomycin)、博萊黴素(bleomycin)、光輝黴素(mithramycin)、安曲黴素(anthramycin)、鏈佐黴素(streptozotocin)、短桿菌素D (gramicidin D)、絲裂黴素(mitomycin) (例如絲裂黴素C));卡奇黴素(calicheamicin);抗有絲分裂劑(包括例如類美登素(maytansinoid) (諸如DM1、DM3及DM4)、奧瑞他汀(包括例如單甲基奧瑞他汀E (MMAE)及單甲基奧瑞他汀F (MMAF))、尾海兔素(dolastatin)、念珠藻素(cryptophycin)、長春花屬生物鹼(vinca alkaloid) (例如長春新鹼(vincristine)、長春鹼(vinblastine)、長春地辛(vindesine)、長春瑞濱(vinorelbine))、紫杉烷(taxane) (例如太平洋紫杉醇(paclitaxel)、多西他賽(docetaxel)或新穎紫杉烷)、特吡萊辛(tubulysin)及秋水仙鹼(colchicine));拓樸異構酶抑制劑(topoisomerase inhibitor) (例如,伊立替康(irinotecan)、拓樸替康(topotecan)、喜樹鹼(camptothecin)、依託泊苷(etoposide)、替尼泊甙(teniposide)、安吖啶(amsacrine)或米托蒽醌(mitoxantrone));HDAC抑制劑(例如,伏立諾他(vorinostat)、羅米地辛(romidepsin)、西達本胺(chidamide)、帕比司他(panobinostat)或貝林諾他(belinostat));蛋白酶體抑制劑(例如,肽基酸);以及放射性同位素,諸如At211
、I131
、I125
、Y90
、Re186
、Re188
、Sm153
、Bi212
或213
、P32
及Lu之放射性同位素,包括Lu177
。同位素螯合劑之實例包括(但不限於)乙二胺四乙酸(ethylenediaminetetraacetic acid,EDTA)、二伸乙基三胺-N,N,N',N",N"-五乙酸酯(DTPA)、1,4,7,10-四氮雜環十二烷-N,N',N",N"'-四乙酸酯(DOTA)、1,4,7,10-肆(2-羥丙基)-1,4,7,10-四氮雜環十二烷(THP)、三伸乙基四胺-N,N,N',N",N"',N"'-六乙酸酯(TTHA)、1,4,7,10-四氮雜環十二烷-N,N',N",N"'-肆(亞甲基膦酸酯) (DOTP)及巰基乙醯基三甘胺酸(MAG3)。 在一些實施例中,當使用醣蛋白-酬載共軛物進行偵測時,酬載可為標記。標記包括(但不限於)直接被偵測之標記或部分(諸如螢光標記、發色標記、電子緻密標記、化學發光標記及放射性標記),以及例如經由酶促反應或分子相互作用間接被偵測之部分,諸如酶或配體。例示性標記包括(但不限於)放射性同位素P32
、C14
、I125
、H3
及I131
;螢光團,諸如稀土螯合物或螢光素(fluorescein)及其衍生物、若丹明(rhodamine)及其衍生物、丹磺醯基(dansyl)、繖酮(umbelliferone);螢光素酶,例如螢火蟲螢光素酶及細菌螢光素酶;螢光素(luciferin);2,3-二氫酞嗪二酮;辣根過氧化酶(horseradish peroxidase,HRP);鹼性磷酸酶;β-半乳糖苷酶;葡萄糖澱粉酶;溶菌酶;醣氧化酶,例如葡萄糖氧化酶、半乳糖氧化酶及葡萄糖-6-磷酸去氫酶;雜環氧化酶,諸如尿酸酶及黃嘌呤氧化酶,其與採用過氧化氫來氧化染料前驅體之酶(諸如HRP、乳過氧化酶或微過氧化酶)偶合;生物素/抗生物素蛋白;自旋標記;噬菌體標記;穩定自由基及類似標記。在另一實施例中,標記係正電子發射體。正電子發射體包括(但不限於) Ga68
、F18
、Cu64
、Y86
、Br76
、Zr89
及I124
。 在一些實施例中,連接基團具有能夠與醣蛋白上所存在之親電子基團反應的官能基。此類親電子基團之實例包括(但不限於)醛及酮羰基。在一些實施例中,連接基團之反應性官能基之雜原子可與醣蛋白上之親電子基團反應且與醣蛋白單元形成共價鍵。此類反應性官能基之非限制性實例包括(但不限於)醯肼、肟、胺基、肼、硫縮胺脲(thiosemicarbazone)、肼羧酸酯及芳基醯肼。 在一些實施例中,共軛劑具有能夠與醣蛋白上所存在之親電子基團反應的官能基。此類親電子基團之實例包括(但不限於)疊氮基、醛及酮基。在一些實施例中,共軛劑之反應性官能基之雜原子可與醣蛋白上之親電子基團反應且與醣蛋白單元形成共價鍵。此類反應性官能基之非限制性實例包括(但不限於)炔烴、二苯并環辛炔、醯肼、肟、胺基、肼、硫縮胺脲、肼羧酸酯及芳基醯肼。 在一些實施例中,連接基團具有能夠連接共軛劑及酬載之官能基。此類連接基團之實例包括(但不限於)不可裂解的連接基團及可裂解的連接基團。在一些實施例中,不可裂解的連接基團包括(但不限於)具有2至20個碳原子之直鏈或分支鏈烷基、環烷基、烯基、環烯基、炔基、芳基、雜芳基、烷氧基、醯基、烷基胺或芳基胺基。在一些實施例中,可裂解的連接基團包括(但不限於)含有雙硫鍵之連接基團、酸不穩定連接基團、光不穩定連接基團、肽酶不穩定連接基團及酯酶不穩定連接基團。 呈現以下實例來說明本發明之某些實施例,但不應將該等實例理解為限制本發明之範疇。本發明之範疇包括如圖1中所示自三甘露糖基核心抗體產生具有一種或兩種酬載的均質ADC的一步法或依序法。 實例1. 藉由使用β1,4-半乳糖苷酶及神經胺糖酸苷酶來製備賀癌平抗體 為了自賀癌平抗體(Roche Inc)移除N-聚醣之半乳糖及唾液酸部分,將10 mg賀癌平抗體在37℃下用20 μl β1,4-半乳糖苷酶(NEB,P0745L,8單位/μl)及5 µl α2-3,6,8神經胺糖酸苷酶(NEB,P0720L,50單位/μl)在1×糖緩衝劑(GlycoBuffer)1 (NEB,總體積1 ml)中處理24小時。進一步向反應物添加10 μl β1,4-半乳糖苷酶(NEB,P0745L,8單位/μl)且使反應在37℃下再進行24小時以獲得G0F/G0抗體樣品。藉由使用rProtein A Sepharose Fast Flow (GE Healthcare,17-1279-02)純化抗體樣品。在純化之後,對抗體樣品進行折合質量層析分析。圖2中所示之結果揭示,樣品中主要量之抗體係G0F (具有分子量50,600 Da之重鏈)且僅少量係G0 (無海藻糖;具有分子量50,451 Da之重鏈)。 實例2. 賀癌平轉化成三甘露糖基核心抗體 將來自實例1之10 mg G0F/G0賀癌平抗體在37℃下用20 μl β-N-乙醯葡萄糖胺酶S (NEB,P0744L,4單位/μl)在1×糖緩衝劑1 (NEB,總體積1 ml)中處理24小時。向反應物添加10 μl β-N-乙醯葡萄糖胺酶S (NEB,P0744L,4單位/μl)且使反應在37℃下繼續再進行24小時以獲得經消化之抗體樣品。藉由使用rProtein A Sepharose Fast Flow (GE Healthcare,17-1279-02)純化經消化之抗體樣品。在純化之後,對抗體樣品進行折合質量層析分析。圖3中所示之結果揭示,獲得了具有分子量50,194 Da之重鏈的三甘露糖基核心賀癌平抗體且幾乎所有的G0F及G0賀癌平抗體皆被轉化為三甘露糖基核心抗體。這說明β-N-乙醯葡萄糖胺酶S能夠以高效率將G0F及G0抗體轉化為具有三甘露糖基核心的抗體。實例3. 藉由甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶(MGAT-1;GnT-1)使GlcNAc與α-3甘露糖在三甘露糖基核心賀癌平抗體之各重鏈之一個臂中共軛 將來自實例2之三甘露糖基核心賀癌平抗體(40 μg)與UDP-GlcNAc (最終濃度2.5 mM) (Sigma,U4375)在80 μl 1×緩衝劑SP (25 mM 4-嗎啉乙磺酸(MES),10 mM MnCl2
,pH 6.5)中在MGAT-1 (0.15 μg;R&D,8334-GT)存在下在37℃下培育16小時。對產物進行折合質量層析分析。如圖4中所示之結果,相比於具有分子量50,195 Da之重鏈的三甘露糖基核心賀癌平抗體,獲得了重鏈另外含有一個GlcNAc (分子量203 Da)且分子量係50,398 Da的抗體產物。這證明MGAT-1僅將一個N-乙醯葡萄糖胺轉移至其受質蛋白。實例4. 藉由MGAT-1及甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶(MGAT-2;GnT-2)將三甘露糖基核心賀癌平抗體轉化為G0F/G0賀癌平 將來自實例2之三甘露糖基核心賀癌平抗體(40 μg)及UDP-GlcNAc (最終濃度2.5 mM) (Sigma,U4375)在80 μl 1×緩衝劑SP (25 mM MES,10 mM MnCl2
,pH 6.5)中在MGAT-1 (0.15 μg)及MGAT-2 (0.1 μg)存在下在37℃下培育16小時。在培育之後,對反應產物進行折合質量層析分析。如圖5中所示之結果,相比於具有分子量50,194 Da之重鏈的三甘露糖基核心賀癌平抗體,獲得了帶有少量G0之G0F抗體產物,其重鏈另外含有兩個GlcNAc (分子量203 Da×2)且分子量係50,600 Da。此等結果指示,藉由組合MGAT-1、MGAT-2及N-乙醯葡萄糖胺,可將三甘露糖基核心抗體轉為G0/G0F抗體。實例5. 三甘露糖基核心賀癌平抗體並非MGAT-2之受質 MGAT-2僅在三甘露糖基核心已具有連接至α(1,3)甘露糖之GlcNAc糖時才將GlcNAc糖自UDP-GlcNAc轉移至三甘露糖基核心之α(1,6)甘露糖。換言之,若沒有GlcNAc糖連接至三甘露糖基核心之α(1,3)甘露糖,則MGAT-2將不能把GlcNAc糖轉移至α(1,3)甘露糖或α(1,6)甘露糖。為了確認以上觀察結果,將來自實例 2
之三甘露糖基核心賀癌平抗體(40 μg)與UDP-GlcNAc (2.5 mM)在80 μl 1×緩衝劑SP (25 mM MES,10 mM MnCl2
,pH 6.5)中在MGAT-2 (0.1 μg)存在下在37℃下培育16小時。對產物進行折合質量層析分析。在質譜中,三甘露糖基核心抗體之分子量無顯著變化(數據未示出)。此結果表明,三甘露糖基核心並非MGAT-2之受質,且MGAT-2需要MGAT-1之轉化產物來產生G0F/G0型抗體。實例6. 藉由MGAT-1使GlcNAz與三甘露糖基核心賀癌平抗體之各重鏈之一個臂之末端α-3甘露糖共軛 將來自實例2之三甘露糖基核心賀癌平抗體(40 μg)與UDP-GlcNAz (1 mM) (R&D,ES104-100)在80 μl 1×緩衝劑SP (20 mM Tris,10 mM MnCl2
,pH 6.5)中在MGAT-1 (0.25 μg;R&D,8334-GT)存在下在37℃下培育16小時。對產物進行折合質量層析分析。如圖6中所示之結果,相比於具有分子量50,195 Da之重鏈的三甘露糖基核心賀癌平抗體,獲得了重鏈另外含有一個GlcNAz (分子量244 Da)且分子量係50,438 Da的抗體產物。此結果表明,UDP-GlcNAz係MGAT-1的受質之一,且GlcNAz可經由MGAT-1連接至三甘露糖基核心賀癌平抗體之各重鏈之臂中之α-3甘露糖,形成三甘露糖基賀癌平-2GlcNAz抗體。實例7. 藉由MGAT-1及MGAT-2使UDP-GlcNAz與三甘露糖基核心賀癌平抗體共軛產生三甘露糖基賀癌平-4GlcNAz 將來自實例2之三甘露糖基核心賀癌平抗體(2 mg)與UDP-GlcNAz (1 mM)在800 μl 1×緩衝劑SP (25 mM MES,10 mM MnCl2
,pH 6.5)中在兔MGAT-1 (25 μg)及大鼠MGAT-2 (10 μg)存在下在37℃下培育16小時。在培育之後,對反應產物分別進行折合質量層析分析及完整質量層析分析。如圖7A
中所示之折合質量層析結果,相比於具有分子量50,194 Da之重鏈的三甘露糖基核心賀癌平抗體,獲得了三甘露糖基賀癌平-4GlcNAz抗體產物,其中重鏈含有兩個GlcNAz分子(分子量244 Da × 2 = 488)且各重鏈之分子量係50,680 Da。此結果表明,GlcNAz經由MGAT-1及MGAT-2與三甘露糖基核心賀癌平抗體之各重鏈之α-3甘露糖及α-6甘露糖共軛。藉由完整質量層析進一步確認此結果。如圖7B中所示之結果,相比於分子量147,237 Da之全三甘露糖基核心賀癌平抗體,獲得了G0F三甘露糖賀癌平-4GlcNAz抗體產物,其含有四個GlcNAz分子(分子量244 Da × 4 = 976 Da)且分子量係148,213 Da。吾人之結果進一步證明,UDP-GlcNAz係MGAT-1及MGAT-2的受質之一,且吾人能夠成功地以吾人之一步法假設來合成中間物四疊氮基抗體。實例8. 三甘露糖基核心賀癌平抗體並非MGAT-2與GlcNAz共軛之受質 將來自實例2之三甘露糖基核心賀癌平抗體(40 μg)與UDP-GlcNAz (1 mM) (R&D ES104-100)在80 μl 1×緩衝劑SP (25 mM MES,10 mM MnCl2
,pH 6.5)中在大鼠MGAT-2 (0.25 μg)存在下在37℃下培育16小時。對產物進行折合質量層析分析。圖8顯示,在質譜中,三甘露糖基核心抗體之分子量無顯著變化,且表明因為實例5,所以三甘露糖基抗體並非MGAT-2之受質。實例9. 三甘露糖基賀癌平-4
GlcNAz抗體與DBCO-(PEG)4
-DM1共軛產生具有DAR4之賀癌平ADC 在實例7中,產生在4個末端甘露糖處各自附接4個GlcNAz中之一者的三甘露糖基抗體。為完成本發明之一步法假設,使用DBCO-(PEG)4
-DM1將毒性酬載偶合至三甘露糖基賀癌平-4GlcNAz,產生具有DAR4之ADC。在25℃下向含有自實例7獲得之5 mg/mL三甘露糖基-4GlcNAz賀癌平抗體的50 μL緩衝劑(25 mM MES;pH 6.5)慢慢添加5 μL DBCO-(PEG)4
-DM1 (10 mM,於DMSO中)以進行點擊化學反應隔夜。在反應之後,經由Amicon Ultra-15離心過濾裝置純化抗體產物,獲得三甘露糖基賀癌平-4 (GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC。對產物進行折合質量層析分析。圖9A中之結果揭示,相比於具有4個GlcNAz之親本三甘露糖基抗體,反應產物三甘露糖基賀癌平-4 (GlcNAc-三唑-DBCO-(PEG)4
-DM1)之重鏈的分子量係53,509 Da,此意謂已有兩個DBCO-(PEG)4
-DM1分子(分子量1,413 Da × 2 = 2,826)與抗體的各重鏈共軛。藉由完整質量層析分析進一步確認此結果。圖9B中之結果揭示,相比於分子量約148,224 Da之三甘露糖基賀癌平-4GlcNAz抗體,獲得了三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC產物,其含有四個DBCO-(PEG)4
-DM1分子(分子量1,413 Da × 4 = 5,652 Da)且分子量係153,876 Da。實例7及9之結果指示,藉由直接組合MGAT-1、MGAT-2及GlcNAz反應與DBCO-(PEG)4
-DM1點擊化學反應,由三甘露糖基抗體產生了ADC-4DM1產物。因此,吾人成功使得本發明中吾人之用於產生ADC的一步法假設合理化。實例10. 藉由DBCO-(PEG)4
-DM1使第一酬載與三甘露糖基賀癌平-2GlcNAz之重鏈之各臂中之末端GlcNAz共軛 實例4至9證明了本發明中用於產生ADC之一步法產生具有均質DAR 4之位點特異性ADC的可行性。在此等成功結果之基礎上進行研究來證明圖1中所示之依序法。為合成第一中間產物,使用DBCO-(PEG)4
-DM1來偶合酬載,從而連接反應物抗體之重鏈之各末端GlcNAz。向含有自實例6獲得之2 mg/mL三甘露糖基賀癌平-2GlcNAz抗體的350 μL緩衝劑(25 mM MES;pH 6.5)慢慢添加14 μL DBCO-(PEG)4
-DM1 (10 mM,於DMSO中)。將反應混合物在氬氣下在25℃下攪拌隔夜以進行點擊化學反應。在反應之後,經由Amicon Ultra-15離心過濾裝置過濾抗體產物,獲得三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)中間物。對產物進行折合質量層析分析。如圖10中所示之結果,相比於三甘露糖基賀癌平-2GlcNAz抗體,分子量51,852 Da之三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)中間物之重鏈之一個臂含有額外一個分子量1414 Da之DBCO-(PEG)4
-DM1分子。實例11. 藉由MGAT-2使第二GlcNAz與三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC之重鏈之各臂中之末端α-6甘露糖共軛 將自實例10獲得之三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)及UDP-GlcNAz (1 mM) (R&D ES104-100)在500 μl 1×緩衝劑(25 mM MES,10 mM MnCl2
,pH 6.5)中在大鼠MGAT-2 (15 μg)存在下在37℃下培育16小時。在反應之後,經由Amicon Ultra-15離心過濾裝置過濾抗體產物,獲得三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)。對產物進行折合質量層析分析。如圖11中所示之結果,相比於親本三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1),三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)之重鏈各自含有額外一個GlcNAz分子(MW=244),分子量係52,097 Da。此結果指示MGAT-2係一種受質非常靈活的酶且將UDP-GlcNAz轉化為大官能基抗體,例如三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1),產生用於雙重酬載ADC產物之中間物。 實例12. 構築抗體之各臂上具有一個MMAE及一個DM1之DAR4 ADC賀癌平產物 在實例11中,產生三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)中間物。為完成圖1中所示之本發明依序法,使用DBCO-(PEG)12
-MMAE將毒性酬載偶合至三甘露糖基賀癌平-2GlcNAz 2 (GlcNAc-三唑-DBCO-(PEG)4
-DM1)且產生具有DAR4及兩種酬載之ADC。 向含有自實例11獲得之2.5 mg/mL三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC的76 μL 1×緩衝劑(25 mM MES,pH 6.5)慢慢添加3.8 μL DBCO-(PEG)12-
MMAE (10 mM,於DMSO中)。將反應混合物在氬氣下在25℃下攪拌隔夜以進行點擊化學反應。在反應之後,經由Amicon Ultra-15離心過濾裝置過濾抗體產物,獲得三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)-2(GlcNAc-三唑-DBCO-(PEG)12
-MMAE) ADC。在純化之後,隨後對產物進行完整質量層析分析。如圖12中所示之結果,相比於分子量151,050 kD之親本三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1),所獲得之三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)-2(GlcNAc-三唑-DBCO-(PEG)12
-MMAE) ADC含有額外兩個DBCO-(PEG)12
-MMAE分子(MW=1648 × 2 = 3,296)且分子量係154,345 Da。此結果表明,本發明方法可精確控制兩個不同酬載(例如DBCO-PEG4
-DM1及DBCO-(PEG)12
-MMAE)與三甘露糖基賀癌平之共軛。實例13. 構築抗體之各臂上具有一個MMAF及一個DM1之DAR4 ADC賀癌平產物 向含有自實例11獲得之2.5 mg/mL三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC的76 μL 1×緩衝劑(25 mM MES,pH 6.5)慢慢添加3.8 μL DBCO-MMAF (10 mM,於DMSO中)。將反應混合物在氬氣下在25℃下攪拌隔夜以進行點擊化學反應。在反應之後,經由Amicon Ultra-15離心過濾裝置過濾抗體產物,獲得三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)-2(GlcNAc-三唑-DBCO-MMAF) ADC。對產物進行完整質量層析分析。如圖13中所示之結果,相比於親本三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC (MW = 151,050),所獲得之三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4
-DM1)-2(GlcNAc-三唑-DBCO-MMAF) ADC含有額外兩個分子量2,038 Da之DBCO-MMAF分子且分子量係153,082 Da。此結果表明,本發明方法可精確控制不同種的酬載(例如DBCO-(PEG)4
-DM1、DBCO-(PEG)12
-MMAE及DBCO-MMAF)與三甘露糖基賀癌平之共軛。 總而言之,藉由組合MGAT-1、MGAT-2及GlcNAz酶促反應與DBCO-酬載化學反應,吾人使得吾人之本發明假設合理化。吾人能夠用吾人之一步法產生具有DAR4或DAR2之均質位點特異性ADC產物。另一方面,本發明亦適用於藉由依序法合成具有兩種酬載之均質位點特異性ADC產物。實例14. 三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1)之結合親和力分析 藉由以上所述之方法構築三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC。自(Roche Inc)購得針對Her2/Neu分子之Kadcyla。向NUNC Maxisorp培養盤之各孔添加ERBB2-ECD (ebioscience BMS362) (100 ng/孔)且將培養盤擱置一旁,在4℃下隔夜。用1× PBS-T (0.1%)洗滌培養盤以移除未塗佈之試劑。向培養盤之孔添加3%脫脂奶,且將培養盤擱置一旁,在室溫下歷時2小時。將培養盤用1× PBS-T (0.1%)洗滌3次,使其乾燥,且隨後儲存於-20℃下供進一步使用。向培養盤添加連續稀釋度自1×10-6
g/mL至1×10-12
g/mL的個別抗體,且將培養盤在37℃下培育1小時。添加與辣根過氧化酶(HRP)共軛之山羊抗人類IgG,培育1小時,且隨後添加3,3',5,5'-四甲基聯苯胺(TMB)。讀取OD405以計算活性。每個研究重複三次,且數據呈現為平均值±SD。使用Prism軟體,使用OD讀數及抗體濃度製成多散佈圖。圖14中所示之結果揭示,三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC之曲線與陽性對照Kadcyla及三甘露糖基賀癌平-4GlcNAz之曲線幾乎相同。陰性對照抗mesothelien顯示與Her2/Neu分子無結合親和力。此結果表明,三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC與Her2/Neu分子之結合親和力不受所進行之修飾的影響。 實例15. 三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC之細胞毒性作用 將Her2/Neu高表現細胞株SK-BR-3、Her2/Neu中等表現細胞株HCC-1954及Her2/Neu低表現細胞株MDA-MB-231稀釋至106
個細胞/ml。在向96孔盤之孔添加100 μL經稀釋之細胞培養物之後,將細胞在37℃下培育24小時。向各孔添加80 μl完全培養基,且隨後以不同劑量向不同孔添加20 μl三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC。在將培養盤在37℃下培育48小時之後,向各孔中添加100 μl CellTiter-Glo®試劑。在室溫下再培育10分鐘之後,用光度計量測孔之發光(光)。三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC對Her2/Neu高表現細胞株SK-BR-3及Her2/Neu中等表現細胞株HCC-1954之IC50值分別係4.7 nM及14 nM。IC50值亦顯示,所有測試抗體對Her2/Neu低表現細胞株MDA-MB-231均無抗增殖作用。此結果表明,就Kadcyla而言,三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC不僅對Her2/Neu高表現細胞有細胞毒性,對Her2/Neu中等表現細胞亦有細胞毒性,且三甘露糖基ADC平台對抗體之修飾不影響其生物活性。 實例16. 由F293細胞產生三甘露糖基核心曲妥珠單抗抗體及三甘露糖基核心抗TMC33抗體 構築含有編碼β-N-乙醯葡萄糖胺酶S之cDNA的質體pTCAE8.3-exo-Gal且將其共轉染至兩個F293細胞株中以分別表現三甘露糖基曲妥珠單抗(抗Her2抗體)及三甘露糖基抗跨膜及捲曲螺旋域家族3 (TMCC3)抗體。在培育之後,收集兩個細胞培養物之上清液且藉由使用rProtein A Sepharose Fast Flow (GE Healthcare,17-1279-02)分別純化其中所含之抗體。在純化之後,對經純化之抗體樣品進行折合質量層析分析。圖15A中所示之結果揭示,當與自僅轉染曲妥珠單抗基因之F293細胞分離之抗體進行比較時,自同樣轉染β-N-乙醯葡萄糖胺酶S及曲妥珠單抗基因之相同細胞獲得的曲妥珠單抗抗體之重鏈顯示分子量50,195 Da之峰,其指示所得曲妥珠單抗抗體係三甘露糖基核心抗體。在轉染抗TMCC3抗體基因之相同細胞中見到類似結果(圖15B)。結果表明,自商業細胞株大量生產三甘露糖基抗體係可行的且適用於工業CMC擴增。實例17. 藉由MGAT-1及MGAT-2使UDP-GlcNAz與細胞表現之三甘露糖基核心曲妥珠單抗抗體共軛產生三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC 根據實例7中所述之方法,將自實例16獲得之2 mg三甘露糖基核心曲妥珠單抗抗體(由哺乳動物細胞產生)及UDP-GlcNAz (1 mM)在800 μl 1×緩衝劑SP (25 mM MES,10 mM MnCl2
,pH 6.5)中在兔MGAT-1 (25 μg)及大鼠MGAT-2 (10 μg)存在下在37℃下培育16小時。在培育之後,對反應產物進行折合質量層析分析及完整質量層析分析。如圖16A中所示之折合質量層析結果,相比於具有分子量50,194 Da之重鏈的三甘露糖基核心曲妥珠單抗抗體,獲得了三甘露糖基曲妥珠單抗-4GlcNAz抗體產物,其中重鏈含有另外兩個分子量約244 Da × 2 = 488之GlcNAz分子且各重鏈之分子量係約50,680 Da。此結果表明,GlcNAz可經由MGAT-1及MGAT-2與由哺乳動物細胞產生之三甘露糖基核心曲妥珠單抗抗體之各重鏈的α-3甘露糖及α-6甘露糖共軛。 根據實例9中所述之方法,在25℃下向含有以上所獲得之三甘露糖基曲妥珠單抗-4GlcNAz抗體之Tris緩衝劑(pH 7.0)慢慢添加DBCO-(PEG)4
-DM1以進行點擊化學反應歷時16小時。在反應及純化之後,對產物進行折合質量層析分析及完整質量層析分析。圖16B中之折合質量層析分析結果揭示,產物重鏈之分子量係53,509 Da,這暗示著兩個DBCO-(PEG)4
-DM1分子(分子量1,413 Da × 2 = 2,826)已與三甘露糖基曲妥珠單抗-4GlcNAz抗體之重鏈共軛。由圖16C中之完整質量層析分析結果進一步確認此結果。此結果揭示,獲得了三甘露糖基-4(GlcNAc-三唑-DBCO-(PEG)4
-DM1) ADC產物,其含有四個DBCO-(PEG)4
-DM1分子(分子量1,413 Da × 4 = 5,652 Da)且分子量係約153,868 Da。 預期熟習此項技術者能想到如上述例示性實例中所闡述的本發明之諸多修改及變更。因此,本發明應僅受隨附申請專利範圍限制。
圖1顯示用於製造三甘露糖基抗體藥物共軛物之一步策略及依序策略。 圖2顯示實例1之折合質量(reduced mass)層析分析的結果。結果顯示,藉由β1,4半乳糖苷酶及神經胺糖酸苷酶之處理產生了G0F/G0型賀癌平(Herceptin)。 圖3顯示實例2之折合質量層析分析的結果。結果顯示,G0F/G0型賀癌平經N-乙醯葡萄糖胺酶S轉化為三甘露糖基核心抗體。 圖4顯示實例3之折合質量層析分析的結果。結果顯示,GlcNAC藉由MGAT-1與三甘露糖基賀癌平各位點上之末端甘露糖之一個臂共軛。 圖5顯示實例4之折合質量層析分析的結果。結果顯示,三甘露糖基賀癌平經MGAT-2及MGAT-1轉化為G0/G0F型賀癌平。 圖6顯示實例6之折合質量層析分析的結果。結果顯示,MGAT-1使UDP-GlcNAz與三甘露糖基賀癌平各位點上之末端甘露糖之一個臂共軛。 圖7A顯示實例7之折合質量層析分析的結果;而圖7B顯示實例7之完整質量(intact mass)層析分析的結果。結果顯示,MGAT-1及MGAT-2使UDP-GlcNAz與三甘露糖基賀癌平共軛而產生G0F/G0型賀癌平,其中4個疊氮基在末端N-乙醯葡萄糖胺中。 圖7A及圖7B顯示實例7之完整質量層析分析的結果。結果顯示,MGAT-1及MGAT-2使UDP-GlcNAz與三甘露糖基賀癌平共軛而產生G0F/G0型賀癌平,其中4個疊氮基在末端N-乙醯葡萄糖胺中。 圖8顯示實例8之折合質量層析分析的結果。結果證明,三甘露糖基賀癌平並非用於共軛GlcNAz之MGAT-2的受質。 圖9A顯示實例9之折合質量層析分析的結果;而圖9B顯示實例9之完整質量層析分析的結果。該等圖之結果顯示,DBCO-(PEG)4
-DM1藉由點擊化學反應與三甘露糖基賀癌平-4GlcNAz共軛,產生具有DAR4之賀癌平ADC。 圖10顯示實例10之折合質量層析分析的結果。該圖之結果顯示,第一酬載經MGAT-1及DBCO-(PEG)4
-DM1與三甘露糖基-2GlcNAz賀癌平抗體之重鏈之各臂共軛。 圖11顯示實例11之折合質量層析分析的結果。該圖之結果顯示,第二GlcNAz使α-6甘露糖經MGAT-2與三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4-DM1) ADC之重鏈之各臂共軛。這說明MGAT-2係一種受質非常靈活的酶且將UDP-GlcNAz轉化為大官能基抗體,例如三甘露糖基賀癌平-2(GlcNAc-三唑-DBCO-(PEG)4-DM1),產生用於雙重酬載ADC產物之中間物。 圖12顯示實例12之完整質量層析分析的結果。該圖之結果顯示,藉由向由實例11之產物產生的中間物三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4-DM1)添加DBCO-(PEG)12
-MMAE,產生了在抗體之各臂上具有一個MMAE及一個DM1的DAR4 ADC賀癌平產物。 圖13顯示實例13之完整質量層析分析的結果。結果顯示,藉由向由實例11之產物產生的中間物三甘露糖基賀癌平-2GlcNAz-2(GlcNAc-三唑-DBCO-(PEG)4-DM1)添加DBCO-MMAF,產生了在抗體之各臂上具有一個MMAF及一個DM1的DAR4 ADC賀癌平產物。 圖14顯示如實例14中所述之Kadcyla及三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4-DM1)的結合ELISA。結果指示,Kadcyla與三甘露糖基賀癌平-4(GlcNAc-三唑-DBCO-(PEG)4-DM1)產物之間沒有顯著的Kd差異。 圖15A及圖15B顯示實例16之三甘露糖基核心曲妥珠單抗(trastuzumab)抗體之折合質量層析分析的結果。結果顯示,透過哺乳動物細胞株產生了三甘露糖基曲妥珠單抗及三甘露糖基抗TMCC3。 圖16A、圖16B及圖16C顯示實例17之折合質量層析分析及完整質量層析分析的結果。該等圖之結果顯示,產生三甘露糖基曲妥珠單抗之哺乳動物細胞產生了三甘露糖基曲妥珠單抗-4(GlcNAc-三唑-DBCO-(PEG)4-DM1)。
Claims (32)
- 一種用於製備包含式(1)之結構的醣蛋白-酬載共軛物的方法,該方法包含以下步驟: (i) 使包含具有式(2)之聚醣的醣蛋白與β-N-乙醯葡萄糖胺酶反應,產生包含式(3)之三甘露糖基核心的經修飾醣蛋白; (ii) 使包含式(3)之三甘露糖基核心之經修飾醣蛋白與UDP-GlcNAc-(CH2 )0-8 -R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶及甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得兩個GlcNAc-(CH2 )0-8 -R糖分別鍵結至Man2 及Man3 各者之β-1,2位置,且藉此形成式(4)之聚醣部分;以及 (iii) 使兩個共軛劑-連接基團-酬載(payload)與式(4)之聚醣部分反應,其中該兩個共軛劑-連接基團-酬載之該等酬載相同或不同,產生包含式(1)之結構的醣蛋白-酬載共軛物。
- 如請求項1之方法,其中步驟(i)中之該包含具有式(2)之聚醣之醣蛋白及該β-N-乙醯葡萄糖胺酶係由哺乳動物細胞株產生。
- 如請求項2之方法,該哺乳動物細胞株係經SV40轉形之猴腎CV1株(COS-7)、人類胚腎株(293或293T細胞)、幼倉鼠腎細胞(baby hamster kidney cell,BHK)、小鼠塞特利氏細胞(mouse sertoli cell) (TM4細胞)、猴腎細胞(CV1)、非洲綠猴腎細胞(VERO-76)、人類子宮頸癌細胞(HELA)、犬腎細胞(MDCK)、水牛鼠肝細胞(BRL 3A)、人類肺細胞(W138)、人類肝細胞(Hep G2)、小鼠乳房腫瘤細胞(MMT 060562)、TRI細胞、MRC 5細胞、FS4細胞、中國倉鼠卵巢(Chinese hamster ovary,CHO)細胞或骨髓瘤細胞株。
- 如請求項1至3中任一項之方法,其中該醣蛋白係抗體或其片段,例如來自裂解抗體的抗體Fab片段、F(ab')2、Fv片段或Fc片段、scFv-Fc片段、微型抗體、雙功能抗體或scFv。
- 如請求項1之方法,其中R係疊氮基,該共軛劑係炔基,且步驟(iii)中進行之反應係點擊反應(click reaction)。
- 如請求項1之方法,其中R係酮基或醛,該共軛劑係胺基,且步驟(iii)中進行之反應係還原胺化。
- 如請求項1之方法,其中R係酮基或醛,該共軛劑係β-芳基乙胺基,且步驟(iii)中進行之反應係皮克特-施彭格勒反應(Pictet-Spengler reaction)。
- 如請求項1至3或5至7中任一項之方法,其中該連接基團係選自具有2至20個碳原子之直鏈或分支鏈烷基、環烷基、烯基、環烯基、炔基、芳基、雜芳基、烷氧基、醯基、烷基胺或芳基胺基、含有雙硫鍵之連接基團、酸不穩定連接基團、光不穩定連接基團、肽酶不穩定連接基團及酯酶不穩定連接基團。
- 如請求項1至3或5至7中任一項之方法,其中該等酬載係獨立地選自治療劑及標記。
- 如請求項9之方法,其中該治療劑係選自抗代謝物、烷基化劑、類烷基化劑、DNA小溝烷基化劑、蒽環黴素(anthracycline)、抗生素、卡奇黴素(calicheamicin)、抗有絲分裂劑、拓樸異構酶抑制劑(topoisomerase inhibitor)、蛋白酶體抑制劑及放射性同位素。
- 如請求項9之方法,其中該標記係螢光標記、發色標記、電子緻密標記、化學發光標記、放射性標記、酶標記或正電子發射體。
- 一種醣蛋白-酬載共軛物,其包含如請求項1至11中任一項中所定義之式(1)之結構。
- 一種用於製造包含式(5)之結構的醣蛋白-酬載共軛物的方法,, 該方法包含以下步驟: (i) 使包含如請求項1中所定義之式(3)之三甘露糖基核心的經修飾醣蛋白與UDP-GlcNAc-(CH2 )0-8 -R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2 )0-8 -R糖鍵結至Man2 之β-1,2 位置 ,且藉此形成包含式(6)之聚醣部分的醣蛋白;以及 (ii) 使共軛劑-連接基團-酬載與包含式(6)之聚醣部分的醣蛋白反應,產生包含式(5)之結構的醣蛋白-酬載共軛物。
- 如請求項13之方法,其中該醣蛋白係抗體或其片段,例如來自裂解抗體的抗體Fab片段、F(ab')2、Fv片段或Fc片段、scFv-Fc片段、微型抗體、雙功能抗體或scFv。
- 如請求項13之方法,其中R係疊氮基,該共軛劑係炔基,且步驟(ii)中進行之反應係點擊反應。
- 如請求項13之方法,其中R係酮基或醛,該共軛劑係胺基,且步驟(ii)中進行之反應係還原胺化。
- 如請求項13之方法,其中R係酮基或醛,該共軛劑係β-芳基乙胺基,且步驟(ii)中進行之反應係皮克特-施彭格勒反應。
- 如請求項13至17中任一項之方法,其中該連接基團係選自具有2至20個碳原子之直鏈或分支鏈烷基、環烷基、烯基、環烯基、炔基、芳基、雜芳基、烷氧基、醯基、烷基胺或芳基胺基、含有雙硫鍵之連接基團、酸不穩定連接基團、光不穩定連接基團、肽酶不穩定連接基團及酯酶不穩定連接基團。
- 如請求項13至17中任一項之方法,其中該酬載係治療劑或標記。
- 如請求項19之方法,其中該治療劑係選自抗代謝物、烷基化劑、類烷基化劑、DNA小溝烷基化劑、蒽環黴素、抗生素、卡奇黴素、抗有絲分裂劑、拓樸異構酶抑制劑、蛋白酶體抑制劑及放射性同位素。
- 如請求項19之方法,其中該標記係螢光標記、發色標記、電子緻密標記、化學發光標記、放射性標記、酶標記或正電子發射體。
- 一種醣蛋白-酬載共軛物,其包含如請求項13至21中任一項中所定義之式(5)之結構。
- 一種用於製造包含式(7)之結構的醣蛋白-酬載A/B共軛物的方法,, 該方法包含以下步驟: (i) 使包含如請求項1中所定義之式(3)之三甘露糖基核心的經修飾醣蛋白與UDP-GlcNAc-(CH2 )0-8 -R在甘露糖基(α-1,3-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2 )0-8 -R糖鍵結至Man2 之β-1,2位置,且藉此形成包含如請求項13中所定義之式(6)之聚醣部分的醣蛋白; (ii) 使共軛劑-連接基團-酬載A與包含式(6)之聚醣部分的醣蛋白反應,產生包含式(8)之結構的醣蛋白-酬載A共軛物; (iii) 使包含式(8)之結構的醣蛋白-酬載A共軛物與UDP-GlcNAc-(CH2 )0-8 -R在甘露糖基(α-1,6-)-醣蛋白β-1,2-N-乙醯葡萄糖胺基轉移酶存在下反應,其中R係疊氮基、酮基或醛,使得GlcNAc-(CH2 )0-8 -R糖鍵結至Man3 之β-1,2 位置,且藉此形成包含具有式(9)之聚醣-酬載A部分的醣蛋白;以及 (iv) 使共軛劑-連接基團-酬載B與包含具有式(9)之聚醣-酬載A部分的醣蛋白反應,產生包含式(7)之結構的醣蛋白-酬載A/B共軛物, 其中該酬載A與該酬載B相同或不同。
- 如請求項23之方法,其中該醣蛋白係抗體或其片段,例如來自裂解抗體的抗體Fab片段、F(ab')2、Fv片段或Fc片段、scFv-Fc片段、微型抗體、雙功能抗體或scFv。
- 如請求項23之方法,其中R係疊氮基,該共軛劑係炔基,且步驟(ii)/(iv)中進行之反應係點擊反應。
- 如請求項23之方法,其中R係酮基或醛,該共軛劑係胺基,且步驟(ii)/(iv)中進行之反應係還原胺化。
- 如請求項23之方法,其中R係酮基或醛,該共軛劑係β-芳基乙胺基,且步驟(ii)/(iv)中進行之反應係皮克特-施彭格勒反應。
- 如請求項23至27中任一項之方法,其中該連接基團係選自具有2至20個碳原子之直鏈或分支鏈烷基、環烷基、烯基、環烯基、炔基、芳基、雜芳基、烷氧基、醯基、烷基胺或芳基胺基、含有雙硫鍵之連接基團、酸不穩定連接基團、光不穩定連接基團、肽酶不穩定連接基團及酯酶不穩定連接基團。
- 如請求項23至27中任一項之方法,其中該酬載A及該酬載B係獨立地選自治療劑及標記。
- 如請求項29之方法,其中該治療劑係選自抗代謝物、烷基化劑、類烷基化劑、DNA小溝烷基化劑、蒽環黴素、抗生素、卡奇黴素、抗有絲分裂劑、拓樸異構酶抑制劑、蛋白酶體抑制劑及放射性同位素。
- 如請求項29之方法,其中該標記係螢光標記、發色標記、電子緻密標記、化學發光標記、放射性標記、酶標記或正電子發射體。
- 一種醣蛋白-酬載A/B共軛物,其包含如請求項23至31中任一項中所定義之式(7)之結構。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662440075P | 2016-12-29 | 2016-12-29 | |
US62/440,075 | 2016-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201835331A true TW201835331A (zh) | 2018-10-01 |
TWI673363B TWI673363B (zh) | 2019-10-01 |
Family
ID=62709965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106146600A TWI673363B (zh) | 2016-12-29 | 2017-12-29 | 製備醣蛋白-藥物共軛物之方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11085062B2 (zh) |
EP (1) | EP3568161A4 (zh) |
JP (1) | JP6888764B2 (zh) |
KR (1) | KR102294517B1 (zh) |
CN (1) | CN110121365A (zh) |
AU (1) | AU2017388556B2 (zh) |
CA (1) | CA3048452C (zh) |
TW (1) | TWI673363B (zh) |
WO (1) | WO2018126092A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI802902B (zh) * | 2020-06-05 | 2023-05-21 | 財團法人生物技術開發中心 | 含有抗間皮素抗體的抗體-藥物共軛物及其用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111171299B (zh) * | 2020-01-20 | 2021-12-14 | 湖南省林业科学院 | 一种改性水性醇酸树脂的制备方法、大豆基胶黏剂及在竹、木刨花板中的应用 |
WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
WO2023180484A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing ptk7 |
EP4285934A1 (en) | 2022-05-30 | 2023-12-06 | CER Groupe | Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
EP2292271A3 (en) * | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
WO2006026992A1 (en) * | 2004-09-07 | 2006-03-16 | Novozymes A/S | Altered structure of n-glycans in a fungus |
WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
MX2012011648A (es) * | 2010-04-07 | 2012-11-29 | Momenta Pharmaceuticals Inc | Glicanos de alta manosa. |
EP2563753B9 (en) | 2010-04-27 | 2016-07-06 | SynAffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
EP2852610B1 (en) * | 2012-05-23 | 2018-07-11 | Glykos Finland Oy | Production of fucosylated glycoproteins |
CN110201186A (zh) * | 2012-10-23 | 2019-09-06 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
BR112015020885A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | polipeptídeos de ligação hiperglicosilados |
LT2991683T (lt) * | 2013-05-02 | 2019-12-27 | Glykos Finland Oy | Glikoproteino arba glikano konjugatai su toksine medžiaga |
JP6553042B2 (ja) | 2013-09-05 | 2019-07-31 | ブイアイビー ブイゼットダブリュVib Vzw | 変更されたグリコシル化パターンを有するFc含有分子を産生する細胞並びにその方法及び使用 |
EP2935608A1 (en) | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
US9987373B2 (en) | 2013-10-14 | 2018-06-05 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015157446A1 (en) | 2014-04-08 | 2015-10-15 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
KR20230033737A (ko) * | 2014-05-27 | 2023-03-08 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
WO2016109802A1 (en) | 2014-12-31 | 2016-07-07 | Development Center For Biotechnology | Site-specific conjugation through glycoproteins linkage and method thereof |
JP6523748B2 (ja) * | 2015-04-01 | 2019-06-05 | シスメックス株式会社 | 糖タンパク質の製造方法および糖タンパク質 |
-
2017
- 2017-12-29 TW TW106146600A patent/TWI673363B/zh active
- 2017-12-29 WO PCT/US2017/068872 patent/WO2018126092A1/en unknown
- 2017-12-29 AU AU2017388556A patent/AU2017388556B2/en active Active
- 2017-12-29 US US16/470,807 patent/US11085062B2/en active Active
- 2017-12-29 KR KR1020197019261A patent/KR102294517B1/ko active IP Right Grant
- 2017-12-29 EP EP17889215.4A patent/EP3568161A4/en active Pending
- 2017-12-29 CA CA3048452A patent/CA3048452C/en active Active
- 2017-12-29 CN CN201780081469.4A patent/CN110121365A/zh active Pending
- 2017-12-29 JP JP2019534823A patent/JP6888764B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI802902B (zh) * | 2020-06-05 | 2023-05-21 | 財團法人生物技術開發中心 | 含有抗間皮素抗體的抗體-藥物共軛物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2018126092A1 (en) | 2018-07-05 |
AU2017388556B2 (en) | 2020-06-25 |
US11085062B2 (en) | 2021-08-10 |
EP3568161A1 (en) | 2019-11-20 |
EP3568161A4 (en) | 2020-09-02 |
AU2017388556A1 (en) | 2019-07-11 |
US20200087697A1 (en) | 2020-03-19 |
JP2020503031A (ja) | 2020-01-30 |
CA3048452A1 (en) | 2018-07-05 |
CN110121365A (zh) | 2019-08-13 |
CA3048452C (en) | 2021-06-15 |
KR102294517B1 (ko) | 2021-08-27 |
KR20190086029A (ko) | 2019-07-19 |
JP6888764B2 (ja) | 2021-06-16 |
TWI673363B (zh) | 2019-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI673363B (zh) | 製備醣蛋白-藥物共軛物之方法 | |
EP3057618B1 (en) | Glycoengineered antibody, antibody-conjugate and methods for their preparation | |
US20230100074A1 (en) | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A ß(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE | |
EP3058083B1 (en) | Modified glycoprotein, protein-conjugate and process for the preparation thereof | |
EP2935611B1 (en) | Glycoengineered antibody, antibody-conjugate and methods for their preparation | |
Tang et al. | One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates | |
US20160280797A1 (en) | Modified glycoprotein, protein-conjugate and process for the preparation thereof | |
EP0679094B1 (en) | Compounds for targeting | |
US20220088212A1 (en) | C-terminal lysine conjugated immunoglobulins | |
US20210171998A1 (en) | Lysine conjugated immunoglobulins | |
US20170173175A1 (en) | Site-specific antibody-drug glycoconjugates and methods | |
Shi et al. | One-step synthesis of site-specific antibody–drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates | |
US20170009266A1 (en) | Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby | |
Jaramillo et al. | A glyco-engineering approach for site-specific conjugation to Fab glycans | |
US20230340016A1 (en) | Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF | |
CN117580586A (zh) | 用于位点特异性抗体缀合的Fc聚糖重塑及其应用 | |
WO2020101498A1 (en) | Polypeptide conjugates | |
Orwenyo | Chemoenzymatic synthesis of homogeneous glycopeptides and glycoproteins for functional studies |